Laboratorios Farmaceuticos Rovi dividend and valuation

ROVI · BME · EUR

Compare Laboratorios Farmaceuticos Rovi
€63.10Change from previous close: −4.54%Absolute change: −€3.00

Close · November 20, 2026

Valuation

Laboratorios Farmaceuticos Rovi paid €0.96 per share in dividends over the last 12 months (yield 1.5%). Last ex-dividend date: July 13, 2026. The P/E ratio is 16.0. The average price target of 9 analysts is €75.22.

Data as of November 20, 2026

Laboratorios Farmaceuticos Rovi compared with similar companies

Laboratorios Farmaceuticos Rovi's P/E (trailing 12 months): 16.0, −17% against the median of a group of 10 similar companies (19.4).

Laboratorios Farmaceuticos Rovi's metrics compared with similar companies
MetricLaboratorios Farmaceuticos RoviMedian25th–75th percentileBand
P/E (trailing 12 months)16.019.417.1 – 25.7Low
Forward P/E19.915.514.4 – 20.0Middle
EV/EBITDA17.513.39.36 – 14.7High
Price/book4.292.831.94 – 3.28High
Price/sales4.042.222.00 – 3.57High
Gross margin66.2%65.6%47.7% – 77.1%Middle
Operating margin20.2%20.2%13.7% – 23.9%Middle
Net margin24.8%12.8%9.9% – 15.5%High
ROE28.7%15.4%10.7% – 16.8%High
Debt/equity0.130.360.23 – 0.67Low

Group: the stock and up to 10 companies in the same industry (with fewer than 5, related industries too), same region first, with a similar size. Band: low = the lowest quarter of values in the group, middle = 25th to 75th percentile, high = the highest quarter. Negative multiples and multiples above 500 are excluded; a comparison needs at least 5 values. The group is recalculated nightly.

TickerLandia analysisHow it is calculated

Companies in the group: same industry, similar size

Laboratorios Farmaceuticos Rovi: valuation over time

On the latest fiscal year's earnings (2025), Laboratorios Farmaceuticos Rovi's P/E today is 23.0, in line with the median of its last 10 fiscal years (25.1; between 9.66 and 49.9 from 2016 to 2025). Relative to earnings, it costs about the same as in the past. The dividend yield (1.5%) is in line with the median of the last 10 fiscal years (1.4%).

Laboratorios Farmaceuticos Rovi P/E and dividend yield at each fiscal year end
Fiscal yearPrice at year endEarnings per shareP/EDividend per shareYield
2025€63.50€2.7523.1€0.961.5%
2024€62.95€2.6723.6€0.941.5%
2023€60.20€3.2018.8€1.101.8%
2022€36.06€3.739.66€1.293.6%
2021€73.80€2.7626.7€0.961.3%
2020€37.90€1.1034.4€0.381.0%
2019€24.40€0.7134.3€0.180.7%
2018€17.45€0.3549.9€0.080.5%
2017€15.65€0.3544.8€0.120.8%
2016€12.33€0.5323.3€0.181.5%

TickerLandia calculation: closing price on the last trading day of the fiscal year divided by diluted earnings per share from the annual report (positive earnings only); yield = dividend per share for the year divided by the same price. Prices adjusted for splits. Today's P/E is today's price divided by the latest fiscal year's earnings per share, so it compares with the years above; today's yield uses dividends over the last 12 months.

TickerLandia analysisHow it is calculated

Other metrics

Valuation multiples

Market cap
€3.34B
Enterprise value
€3.43B
PEG
1.26
EV/revenue
4.14

Profitability and growth

ROA
10.2%
ROIC
12.3%
Revenue growth (year over year)
26.4%
Earnings growth (year over year)
246.7%

Financial health

Total cash
€70.92M
Total debt
€100.95M
Current ratio
2.68
Quick ratio
1.50
Altman Z-Score
8.37
Piotroski F-Score
5.00

Dividends

Annual dividend per share
€0.96
Dividend yield
1.5%
Payout ratio
23.5%
Ex-dividend date
July 13, 2026

Analysts and estimates

Average price target
€75.22
Median price target
€76.00
High price target
€89.00
Low price target
€67.00
Analysts with a price target
9
Consensus
Buy
Forward EPS
€3.29
EPS estimate, current year
€3.04

Shares and trading

Beta
0.28
Average volume
102.81K
Shares outstanding
51.14M
Float
16.2M
Institutional ownership
16.9%
Insider ownership
68.2%